Antibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13965-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#13965-1-AP, RRID:AB_2143764
- Product name
- MICAL2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated MICAL2 antibody (Cat. #13965-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Exosome-like nanovesicles derived from Phellinus linteus inhibit Mical2 expression through cross-kingdom regulation and inhibit ultraviolet-induced skin aging.
Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement.
A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis.
MICAL2 Facilitates Gastric Cancer Cell Migration via MRTF-A-Mediated CDC42 Activation.
MICAL2 Contributes to Gastric Cancer Cell Proliferation by Promoting YAP Dephosphorylation and Nuclear Translocation.
Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.
MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
miR-205-5p suppresses pulmonary vascular smooth muscle cell proliferation by targeting MICAL2-mediated Erk1/2 signaling.
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation.
Han J, Wu T, Jin J, Li Z, Cheng W, Dai X, Yang K, Zhang H, Zhang Z, Zhang H, Fan R, Zheng S, Liu H, Li Y, Zhao H, Yao C, Lin T, Zhu C, Liu H
Journal of nanobiotechnology 2022 Oct 21;20(1):455
Journal of nanobiotechnology 2022 Oct 21;20(1):455
Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement.
Zhang Z, Liu R, Wang Y, Wang Y, Shuai Y, Ke C, Jin R, Wang X, Luo J
Oncogene 2022 Jan;41(3):334-346
Oncogene 2022 Jan;41(3):334-346
A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis.
Tan Y, Jiang C, Jia Q, Wang J, Huang G, Tang F
Cell death & disease 2022 Apr 23;13(4):401
Cell death & disease 2022 Apr 23;13(4):401
MICAL2 Facilitates Gastric Cancer Cell Migration via MRTF-A-Mediated CDC42 Activation.
Wang Y, Min P, Qi C, Zhao S, Yu M, Zhang Y, Du J
Frontiers in molecular biosciences 2021;8:568868
Frontiers in molecular biosciences 2021;8:568868
MICAL2 Contributes to Gastric Cancer Cell Proliferation by Promoting YAP Dephosphorylation and Nuclear Translocation.
Qi C, Min P, Wang Q, Wang Y, Song Y, Zhang Y, Bibi M, Du J
Oxidative medicine and cellular longevity 2021;2021:9955717
Oxidative medicine and cellular longevity 2021;2021:9955717
Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction.
Xu C, Zhou X, Xie T, Zhou Y, Zhang Q, Jiang S, Zhang R, Liao L, Dong J
Theranostics 2020;10(15):6806-6824
Theranostics 2020;10(15):6806-6824
MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
Zhou W, Liu Y, Gao Y, Cheng Y, Chang R, Li X, Zhou Y, Wang S, Liang L, Duan C, Zhang C
Cancer letters 2020 Jul 28;483:75-86
Cancer letters 2020 Jul 28;483:75-86
miR-205-5p suppresses pulmonary vascular smooth muscle cell proliferation by targeting MICAL2-mediated Erk1/2 signaling.
Tao W, Sun W, Zhu H, Zhang J
Microvascular research 2019 Jul;124:43-50
Microvascular research 2019 Jul;124:43-50
RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment.
Hellweg R, Mooneyham A, Chang Z, Shetty M, Emmings E, Iizuka Y, Clark C, Starr T, Abrahante JH, Schütz F, Konecny G, Argenta P, Bazzaro M
Hormones & cancer 2018 Oct;9(5):326-337
Hormones & cancer 2018 Oct;9(5):326-337
MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation.
Wang Y, Deng W, Zhang Y, Sun S, Zhao S, Chen Y, Zhao X, Liu L, Du J
Acta physiologica (Oxford, England) 2018 Feb;222(2)
Acta physiologica (Oxford, England) 2018 Feb;222(2)
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HepG2 cells, using MICAL2 antibody 13965-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human brain using 13965-1-AP(MICAL2 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human brain using 13965-1-AP(MICAL2 antibody) at dilution of 1:100 (under 40x lens)
- Sample type
- tissue